MDA5抗体阳性皮肌炎患者肺功能显著长期改善:北美单中心纵向队列研究
该研究描述北美MDA5抗体阳性皮肌炎患者的纵向病程和肺部结局。
要点
- 随访期间患者接受多种免疫调节治疗,肺功能指标FVC和DLco显著改善。
- IL-15、PON1酶活性和MDA5抗体滴度与疾病活动显著相关。
核心结论
- 在北美MDA5抗体阳性皮肌炎-间质性肺病队列中,采用以霉酚酸酯、IVIg和利妥昔单抗为主的积极联合免疫调节治疗,疾病死亡率低且肺功能显著改善。
研究设计与样本
- 单中心纵向队列研究,从352例特发性炎症性肌病患者中识别出30例MDA5抗体阳性皮肌炎患者。
主要发现
- 平均随访4.0±0.8年时总体死亡率为2/24。
- 随访时患者平均接受3.1±1.3种治疗,包括79%接受IVIg、58%接受利妥昔单抗、67%接受霉酚酸酯、63%接受糖皮质激素。
- 22例存活间质性肺病患者中18例有1.8±0.6年的纵向随访,FVC和DLco分别改善16%和17%预计值。
- 18例患者中10例有平均6.8±3.4年的长期随访,FVC和DLco分别改善24%和20%预计值。
临床怎么用
- 对MDA5抗体阳性皮肌炎患者应积极联合免疫调节治疗,包括霉酚酸酯、IVIg和利妥昔单抗,以改善肺功能并降低死亡率。
- IL-15、PON1和MDA5抗体滴度可作为潜在疾病活动生物标志物,但需进一步研究验证。
局限性
- 单中心纵向队列研究,样本量较小(30例MDA5抗体阳性皮肌炎患者)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to describe the longitudinal disease course and pulmonary outcomes of North American patients with melanoma differentiation-associated protein 5 (MDA5) antibody-associated dermatomyositis (DM). METHODS: Thirty patients with MDA5 antibody-associated DM were identified in a single-center longitudinal cohort of 352 patients with idiopathic inflammatory myopathies. Longitudinal assessments of patient clinical and laboratory disease characteristics, pulmonary function tests (PFT), and high-resolution computed tomography chest scans were conducted. RESULTS: Eighty percent (n = 24/30) of patients with MDA5 antibody-associated DM had interstitial lung disease (ILD). The overall mortality was low (2/24 at a mean ± SD follow-up of 4.0 ± 0.8 years). At this follow-up, patients were receiving 3.1 ± 1.3 therapies, including 79% receiving intravenous Ig (IVIg), 58% receiving rituximab, 67% receiving mycophenolate, and 63% receiving glucocorticoids. In 18 of 22 surviving patients with ILD who had two-year longitudinal follow-up available at 1.8 ± 0.6 years, improvements of 16% and 17% predicted forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLco) were noted. In 10 of 18 patients with additional long-term follow-up available (mean ± SD 6.8 ± 3.4 years), improvements of 24% and 20% predicted FVC and DLco were noted. MDA5 antibody and interleukin-15 (IL-15) levels and paraoxonase 1 (PON1) enzyme activity correlated significantly with disease activity at baseline and longitudinally. CONCLUSION: In a North American MDA5 antibody-associated DM-ILD cohort treated with aggressive combination immunomodulatory therapy including predominantly mycophenolate, IVIg, and rituximab, disease mortality was low and lung function improved markedly. IL-15, PON1, and MDA5 antibody titers warrant further investigation as disease activity biomarkers in this high-risk population.
引用
- Cheah JX, Bae SS, De Leon T, et al. Marked Long-Term Improvement in Lung Function in Melanoma Differentiation-Associated Protein 5 Antibody-Positive Dermatomyositis Patients: Experience of a Single-Center Longitudinal Cohort in North America. Arthritis Care Res (Hoboken). 2026. PMID: 41556549. doi:10.1002/acr.80004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。